Video Experimental Relacionado
Updated: Jun 26, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: November 1, 2010
Prevenir la anarquía antirretroviral en el África subsahariana
A D Harries1, D S Nyangulu, N J Hargreaves
1National Tuberculosis Control Programme, Community Health Science Unit, Lilongwe, Malawi. adharries@malawi.net
Lancet (London, England)
|August 15, 2001
Resumen
La terapia antirretroviral combinada mejora significativamente la supervivencia del VIH / SIDA, pero se enfrenta a desafíos. El tratamiento a lo largo de toda la vida, la toxicidad de los medicamentos y los regímenes complejos dificultan la adherencia, lo que lleva a la resistencia a los medicamentos y la necesidad de nuevas terapias.
Área de la Ciencia:
- La medicina es la medicina de la medicina.
- Virología Virología.
- Farmacología Farmacología.
Sus antecedentes:
- La terapia antirretroviral combinada (cART) ha transformado la gestión del VIH / SIDA, mejorando dramáticamente la supervivencia de los pacientes en las naciones industrializadas.
- A pesar del éxito de cART, persisten desafíos significativos en el tratamiento y manejo a largo plazo del VIH.
- Cuestiones como los requisitos de tratamiento a lo largo de toda la vida y las toxicidades de los medicamentos afectan los resultados de los pacientes.
Objetivo del estudio:
- Para resaltar los desafíos persistentes en la terapia antirretroviral combinada para el VIH / SIDA.
- Para subrayar el impacto de la adherencia al tratamiento en la resistencia viral.
- Hacer hincapié en la necesidad de nuevas estrategias terapéuticas.
Principales métodos:
- Este estudio es una revisión de los desafíos actuales en el tratamiento del VIH / SIDA.
- Análisis de los factores que contribuyen a la mala adherencia y la resistencia a los medicamentos.
- Revisión de la literatura sobre las limitaciones de los medicamentos antirretrovirales existentes.
Principales resultados:
- El tratamiento del VIH es a menudo de por vida, lo que plantea desafíos de gestión a largo plazo.
- Muchos pacientes experimentan toxicidad del medicamento o luchan con complejos esquemas de dosificación, lo que afecta la adherencia.
- La mala adherencia es un factor primario para la aparición de cepas de VIH resistentes a los medicamentos.
Conclusiones:
- Superar la toxicidad del tratamiento y simplificar los regímenes es crucial para mejorar la adherencia.
- Abordar los problemas de adherencia es esencial para prevenir el desarrollo de la resistencia a los medicamentos.
- El surgimiento de cepas resistentes requiere el desarrollo de nuevos medicamentos antirretrovirales y combinaciones.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
00:36Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
01:29Viruses with RNA Genomes
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...